Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Sotyktu on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Sotyktu selectively inhibits TYK2, a signaling protein involved in the inflammatory pathways that drive psoriasis. Unlike JAK1/2/3 inhibitors, Sotyktu's selective TYK2 mechanism is designed to reduce inflammation while minimizing broader immune suppression.
Sotyktu is intended for adults with moderate-to-severe plaque psoriasis who are candidates for systemic treatment or phototherapy, offering an oral alternative to injectable biologics.
The recommended dose of Sotyktu is 6 mg taken orally once daily, with or without food. Tablets should not be crushed, cut, or chewed.
Sotyktu does not carry a formal FDA boxed warning. As a TYK2 inhibitor, it is mechanistically distinct from JAK1/2/3 inhibitors and does not carry the class-wide JAK inhibitor boxed warning. However, patients and prescribers should be aware of the following important safety information.
Hypersensitivity reactions, including angioedema, have been reported. Sotyktu should be discontinued if a serious hypersensitivity reaction occurs.
Increased risk of infections, including serious infections such as pneumonia and COVID-19, has been observed in clinical trials. Patients should be evaluated for tuberculosis before starting treatment.
Malignancies, including lymphomas, have been observed in clinical trials. Patients should be monitored for signs of malignancy during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Sotyktu is manufactured and marketed by Bristol-Myers Squibb. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating dermatologist confirming moderate-to-severe plaque psoriasis diagnosis. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for plaque psoriasis, Sotyktu is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Sotyktu directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Sotyktu should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Sotyktu through NPP's regulated import pathway, with dermatology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support dermatology care coordination and documentation for Sotyktu access.
Delhi's major hospitals assist patients with prescription support and documentation for Sotyktu.
Bangalore's specialist network offers access coordination for eligible plaque psoriasis patients seeking Sotyktu.
Chennai-based dermatology specialists coordinate Sotyktu access alongside comprehensive psoriasis care.
Hyderabad's care institutions support patients pursuing Sotyktu therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Sotyktu.
Pune-based specialists assist with prescription support and Sotyktu treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Sotyktu.
Kochi's specialist units assist patients with the documentation needed for Sotyktu access.
Chandigarh's care centers support Sotyktu treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Sotyktu access process.
Lucknow-based centers assist patients pursuing Sotyktu therapy.
Bhubaneswar's institutions support access to Sotyktu for eligible patients.
Guwahati's specialists help coordinate Sotyktu access for patients across the Northeast.
Patients in other cities across India can also access Sotyktu through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.jpg)
